REG - Adv Medical Solutns. - Directorate Change

Advanced Medical SolutionsAnnouncement

23/06/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250623:nRSW9347Na&default-theme=true

RNS Number : 9347N  Advanced Medical Solutions Grp PLC  23 June 2025

 

     23 June 2025

            Advanced Medical Solutions Group plc

("AMS", the "Company" or the "Group")

 

            Directorate Change
 
            Juliet Thompson to be Appointed as an Independent Non-Executive Director

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the
world-leading specialist in tissue-healing technologies, is pleased to
announce that our search for an additional Independent Non-Executive Director
has successfully concluded and that Juliet Thompson will be appointed as a
Non-Executive Director and Chair of the Audit Committee following the
conclusion of the AGM on 30 June.

 

Juliet has over 30 years of finance, banking and board experience with
significant focus in the healthcare sector. She is a proven FTSE 250 Audit
Committee Chair and a former investment banker who has spent her career
advising pharmaceutical and medtech companies. She played a leading role in
setting up Code Securities, which was later acquired by Nomura (becoming
Nomura Code) but remained independent. At Nomura Code, Juliet advised
companies in the healthcare and clean tech sectors on their financing and
strategic options. She worked on over 50 transactions including IPOs,
secondary offerings, private placements and M&A. As Nomura Code was
devolved, she joined Stifel with a team from Nomura Code to head up the life
sciences team where she advised CEOs and CFOs in the healthcare sector. She
was Audit Committee Chair at Vectura Group Limited.

 

Juliet has built a diverse portfolio; she is currently a Non-Executive
Director and Chair of the Audit Committees of: Indivior plc, a NASDAQ listed
company working to develop medicines to treat addiction; Novacyt S.A., a
Euronext and AIM listed diagnostic company; and Organox Limited, a private
company spun out of Oxford University developing innovative solutions for
organ preservation prior to transplantation. Juliet holds a BSc in Economics
from the University of Bristol and qualified as a Chartered Accountant and
holds an ACA from the Association of Chartered Certified Accountants.

 

Grahame Cook, Chair of AMS, said: "I am very pleased to welcome Juliet to the
Board of AMS. She has a wealth of Board experience, particularly focused on
healthcare companies, and is a proven Audit Committee Chair. She will be a
valuable addition to our Board."

 

Juliet Thompson commented: "I have followed AMS progress over the last few
years and am excited to be joining the Board as the company continues its
growth journey."

Juliet will immediately be appointed as Chair of the Audit Committee and join
the Nomination and Remuneration Committees. The composition of each of the
Board Committees from 30 June 2025 is therefore confirmed as follows:

 

 Board Committee         Membership
 Audit Committee         Juliet Thompson (Chair)

                         Grahame Cook

                         Douglas Le Fort

                         Susan Searle
 Nomination Committee    Grahame Cook (Chair)

                         Douglas Le Fort

                         Susan Searle

                         Juliet Thompson
 Remuneration Committee  Douglas Le Fort (Chair)

                         Grahame Cook

                         Susan Searle

                         Juliet Thompson

 

The following information is disclosed pursuant to Schedule Two, paragraph (g)
of the AIM Rules for Companies:

 

Juliet Thompson (aged 59 years) holds or has held Directorships and
partnerships in the five years preceding her appointment at AMS as follows:

 

 Current Directorships           Previous Directorships
 Indivior plc                    Angle plc
 OrganOx Ltd                     Leadership Through Sport and Business
 Novacyt Group                   Opus 107 Limited
 Opus Trust Investments Limited  Vectura Group Limited
                                 GI Dynamics, Inc

 

No further information in connection with her appointment is required to be
disclosed under Schedule Two, paragraph (g) of the AIM Rules for Companies.

 

- End -

 

For further information, please visit www.admedsol.com
(http://www.admedsol.com) or contact:

 

 Advanced Medical Solutions Group plc             Tel: +44 (0) 1606 545508
 Chris Meredith, Chief Executive Officer

 Eddie Johnson, Chief Financial Officer

 Michael King, Investor Relations

 ICR Healthcare                                   Tel: +44 (0) 20 3709 5700
 Mary-Jane Elliott / Lucy Featherstone            AMS@icrhealthcare.com

 Investec Bank PLC (NOMAD & Broker)               Tel: +44 (0) 20 7597 5970
 Gary Clarence / David Anderson

 Berenberg (Joint Broker)                         Tel: +44 (0)20 3207 7800
 Toby Flaux / Detlir Elezi / Yasmina Benchekroun

 

About Advanced Medical Solutions Group plc - see www.admedsol.com
(http://www.admedsol.com)

AMS is a world-leading independent developer and manufacturer of innovative
tissue-healing technology, focused on quality outcomes for patients and value
for payers. AMS has a wide range of surgical products including tissue
adhesives, sutures, haemostats, internal fixation devices and internal
sealants, which it markets under its brands LiquiBand®, RESORBA®,
LiquiBandFix8®, LIQUIFIX™, Peters Surgical, Ifabond, Vitalitec and
Seal-G®. AMS also supplies wound care dressings such as silver alginates,
alginates and foams through its ActivHeal® brand as well as under white
label. Since 2019, the Group has made seven acquisitions: Sealantis, an
Israeli developer of innovative internal sealants, Biomatlante, a French
developer and manufacturer of surgical biomaterials, Raleigh, a leading UK
coater and converter of woundcare and bio-diagnostics materials, AFS Medical,
an Austrian specialist surgical business, Connexicon, an Irish tissue
adhesives specialist, Syntacoll, a German specialist in collagen-based
absorbable surgical implants and Peters Surgical, a global provider of
specialty surgical sutures, mechanical haemostasis and internal cyanoacrylate
devices.

 

AMS's products, manufactured in the UK, Germany, France, the Netherlands,
Thailand, India, the Czech Republic and Israel, are sold globally via a
network of multinational or regional partners and distributors, as well as via
AMS's own direct sales forces in the UK, Germany, Austria, France, Poland,
Benelux, India, the Czech Republic and Russia. The Group has R&D
innovation hubs in the UK, Ireland, Germany, France and Israel. Established in
1991, the Group has more than 1,600 employees. For more information, please
see www.admedsol.com (http://www.admedsol.com) .

 

-

.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAPPUUCQUPAUAW